Spermosens Past Earnings Performance

Past criteria checks 0/6

Spermosens's earnings have been declining at an average annual rate of -32.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 42.7% per year.

Key information

-32.5%

Earnings growth rate

2.8%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth rate-42.7%
Return on equity-44.3%
Net Marginn/a
Next Earnings Update28 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Spermosens makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGM:SPERM Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-1044
30 Jun 240-1154
31 Mar 240-1255
31 Dec 230-1265
30 Sep 230-20712
30 Jun 230-20712
31 Mar 230-20812
31 Dec 220-19812
30 Sep 225-1194
30 Jun 228-10103
31 Mar 2211-8111
31 Dec 2112-6100
30 Sep 219-790
30 Jun 217-560
31 Mar 214-340
31 Dec 202-230
31 Dec 190010

Quality Earnings: SPERM is currently unprofitable.

Growing Profit Margin: SPERM is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SPERM is unprofitable, and losses have increased over the past 5 years at a rate of 32.5% per year.

Accelerating Growth: Unable to compare SPERM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SPERM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: SPERM has a negative Return on Equity (-44.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies